Xencor

269 articles with Xencor

• Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19

  3/25/2020

  Xencor, Inc. announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.

• Xencor Reports Fourth Quarter and Full Year 2019 Financial Results

  2/24/2020

  Feb. 24, 2020 21:01 UTC -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--( BUSINESS WIRE )-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a review of recent business and clinical highlights. “Throughout 2019 we

• Xencor to Host Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call on February 24, 2020

  2/18/2020

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2019 financial results after the market closes on Monday, February 24, 2020.

• Xencor to Present at Upcoming February 2020 Investor Conferences

  2/6/2020

  Xencor, Inc. announced that company management will participate in two upcoming conferences

• Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments

  2/5/2020

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb®7195 to Aimmune Therapeutics, Inc.

• Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV

  1/8/2020

  Xencor, Inc. announced it has entered into a technology license agreement in which Gilead Sciences, Inc., will access Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for developing and commercializing GS-9722, Gilead’s first-in-class effector-enhanced broadly neutralizing anti-HIV antibody, which is currently in Phase 1 clinical development.

• Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors

  12/20/2019

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its board of directors.

• Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer

  12/18/2019

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Allen Yang, M.D., Ph.D., as senior vice president and chief medical officer.

• Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting

  12/9/2019

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced initial data from its ongoing Phase 1 dose-escalation study of XmAb®13676, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies

• Xencor to Present at Upcoming Investor Conferences - Nov. 13, 2019

  11/13/2019

  Xencor, Inc. announced that company management will participate in two upcoming conferences

• Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting

  11/6/2019

  Xencor, Inc. announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb®13676, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies will be presented in a poster session during the 61st American Society of Hematology Annual Meeting in Orlando, Florida on Monday, December 9, 2019.

• Xencor Reports Third Quarter 2019 Financial Results

  11/5/2019

  Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, reported financial results for the third quarter ended September 30, 2019 and provided a review of recent business and clinical highlights.

• Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019

  10/29/2019

  Xencor, Inc. announced that it will release third quarter 2019 financial results after the market closes on Tuesday, November 5, 2019.

• Xencor to Present at the 2019 Cantor Global Healthcare Conference

  9/26/2019

  Xencor, Inc announced that company management will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:55 a.m. ET in New York.

• Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

  9/10/2019

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Celia Eckert as vice president, general counsel and corporate secretary.

• Xencor Reports Second Quarter 2019 Financial Results

  8/6/2019

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today reported financial results for the second quarter ended June 30, 2019 and provided a review of recent business and clinical highlights.

• Xencor to Present at Upcoming Investor Conferences - Aug. 1, 2019

  8/1/2019

  Xencor, Inc. announced that company management will participate in three upcoming conferences

• Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019

  7/30/2019

  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release second quarter 2019 financial results after the market closes on Tuesday, August 6, 2019.

• Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.

  6/27/2019

  Xencor, Inc. announced that Paul Foster, M.D., senior vice president and chief medical officer at Xencor, plans to retire from Xencor effective October 31, 2019, following a transition period with a successor.

• Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors

  6/3/2019

  XmAb22841, a CTLA-4 x LAG-3 bispecific antibody, is Xencor’s third tumor microenvironment (TME) activator to enter clinical development